Clinical studies of beta-thioguanine deoxyriboside alone and in combination with arabinosyl cytosine
| Autor: | Gerald P. Bodey, Kenneth B. McCredie, John P. Whitecar, Emil J. Freireich |
|---|---|
| Rok vydání: | 1976 |
| Předmět: |
Purine
Adult Male Cancer Research Time Factors Adolescent medicine.medical_treatment Remission Spontaneous Deoxyribonucleosides Pharmacology chemistry.chemical_compound Neoplasms medicine Humans Neoplasm Metastasis Child Thioguanine Aged Chemotherapy Acute leukemia Leukemia Thionucleosides Guanosine business.industry Cytarabine Deoxyguanosine Leukopenia Middle Aged medicine.disease Thrombocytopenia Oncology chemistry Child Preschool Pediatrics Perinatology and Child Health Toxicity Acute Disease Drug Therapy Combination Female Liver function business Nucleoside medicine.drug |
| Zdroj: | Medical and pediatric oncology. 2(2) |
| ISSN: | 0098-1532 |
| Popis: | Beta-thioguanine deoxyriboside (betaTGdR) is a purine nucleoside derivative which was studied alone or in combination with arabinosyl cytosine (Ara-C) in patients with solid tumors and acute leukemia. No significant responses were observed in 22 patients with solid tumors. The response rate with betaTGdR alone in acute leukemia was 26% and in combination with Ara-C was 24%. Responses were generally of short duration. Toxicity included myelosuppression, nausea, stomatitis, hyperpigmentation, photosensitivity, and liver function abnormalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text